biOasis Technologies Inc. (BTI.V) is delighted to acknowledge and recognize Dr. (Leigh) Anderson, one of its scientific advisors, for his recent award, the 2009 Distinguished Achievement award in Proteomic Science. This award is given by the Human Proteome Organization to highlight outstanding achievements within the field of Proteomic Science. Leigh is considered one of the early pioneers in Proteomic Science and is clearly recognized as a world-leading expert in this field. Leigh’s early work with identifying and measuring human proteins dates back to the 1980’s and has continued with several recent technological and intellectual breakthroughs regarding the human proteome. One of Leigh’s major accomplishments is the invention of the new method called Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) that allows multiplexed quantification of biomarkers in human blood plasma using robust and sensitive mass spectrometric analysis. biOasis is very fortunate to have such expertise within its science team.
“We are delighted to have high caliber Scientists such as Leigh on our team,” says CEO Rob Hutchison. “A very big part of our mandate over the past year has been to attract world recognized scientists like Leigh to help us attain our goal of delivering a biomarker to help physicians diagnose Alzheimer’s, a disease that is growing with epidemic proportions. Leigh, along with another member of our science team, Dr. Terry Pearson, are very near completion of the new SISCAPA blood plasma test for biOasis to measure and validate p97 as a biomarker for Alzheimer’s disease. This award provides recognition from within the industry as to Leigh’s stature and scientific contributions. biOasis congratulates Leigh and his family on achieving this award!”
biOasis Technologies Inc. is a Canadian Life Sciences company focused on the Health Care & Life Sciences market, engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases. It has extensive and comprehensive intellectual property (“IP”) which it obtained, from The University of British Columbia. The Company’s initial area of focus has been on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer’s disease. This IP has been corroborated in double- blinded and successive multi-site clinical trials.
The Company is also accelerating its work on its Blood Brain Barrier Compound Delivery Platform (“B3CDP”) that has been independently verified to shuttle compounds across the Blood Brain Barrier that normally are blocked from entering the brain by this barrier.
To find out more about biOasis Technologies Inc. visit www.bioasis.ca.
Forward Looking Statements
Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the Company’s ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
On Behalf of the Board of Directors
Director and CEO
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”